Clinical Trial Detail

NCT ID NCT04060407
Title CD24Fc With Ipilimumab and Nivolumab to Decrease irAE (CINDI) (CINDI)
Recruitment Not yet recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors OncoImmune, Inc.
Indications

colorectal carcinoma

melanoma

renal cell carcinoma

Therapies

CD24Fc + Ipilimumab + Nivolumab

Age Groups: senior adult

No variant requirements are available.